A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis

OBJECTIVE: To assess the efficacy and safety of sirukumab, an anti–interleukin‐6 monoclonal antibody, for the treatment of patients with active lupus nephritis (LN). METHODS: Patients with class III or class IV LN (as determined by renal biopsy within 14 months of randomization) who had persistent p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rovin, Brad H., van Vollenhoven, Ronald F., Aranow, Cynthia, Wagner, Carrie, Gordon, Robert, Zhuang, Yanli, Belkowski, Stanley, Hsu, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129491/
https://www.ncbi.nlm.nih.gov/pubmed/27110697
http://dx.doi.org/10.1002/art.39722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129491/
https://www.ncbi.nlm.nih.gov/pubmed/27110697
http://dx.doi.org/10.1002/art.39722

Ejemplares similares